1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers

JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1). BIG NEWS for GU Oncology + Kidney Cancer patients! https://t.co/poOKpXP5nJ https://t.co/wP9gu8ppLI

Terrific talk by @dmukherji #ESMO 👉Optimizing use of endocrine therapy and chemotherapy in mCRPC #prostatecancer 👉need to improve implementation of level-1 evidence, manage bone and CV toxicities & sequencing of therapy👇@OncoAlert @urotoday

The RAMPART is thankfully positive making it the second adjuvant immunotherapy trial in #kidneycancer along with KN564 with Pembrolizumab. Driven by high risk group. Included non clear cell but should look at that subgroup more. Awaiting OS. #ESMO25 @OncoAlert

Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science

BEAUTIFUL discussion by @giannatempopatr at #ESMO25, offering a very practical (and balanced) perspective on pros & cons of TMT v cystectomy for #bladdercancer, tackling a wide spectrum of issues. Beyond outcomes she discusses implications of age, cost, treatments after

🥁#ESMO25 ABSTRACT RELEASE DAY🥁 #ESMO25 is shaping up to be one of most impactful conferences in recent memory with #PracticeChangingData in Prostate, Bladder and Kidney Cancers! 💫See list of highlighted abstracts 👇

Please check out our editorial just out in @NatRevUrol on a pragmatic approach to biomarkers for RCC! Many challenges, but with now some emerging promising biomarkers! @arihakimi @EdReznik @motzermd @MSKCancerCenter @MSK_DeptOfMed https://t.co/CaRdSBJP51

1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out @JCO_ASCO !!! Incredibly thankful to my mentors @BraunMDPhD @DrChoueiri @VanAllenLab and all co-authors @DanaFarber @BIDMC_IM @Yale @BrighamWomens Link:

Three-tier risk stratification of #ProstateCancer by PSMA-PET #PROMISE (PPP2): results from an international multi-center registry study. Presented by Madeleine Karpinski @DKTK_. #SNMMI25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/UMS4Leq5zV @SNM_MI

1/5 This comes up in #kidneycancer clinic every few months. And on patient groups just as often. 📊 The ASSURE nomogram shows cumulative disease-free survival (DFS) from time 0 after surgery. Great info… until someone hits the 2-year mark and panics at that 48.8% 3-year number.

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from @OncoAlert...

Congrats @MichaelOng_MD for the stellar talk @ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). @OncoAlert @urotoday @PCF_Science @Daniel_J_George

Amazing long term follow up data from CM214. Dramatic DOR and improved long term outcomes for patients. We have come a long way! ⁦@motzermd⁩ ⁦@ASCO⁩ ⁦@DrChoueiri⁩ ⁦@urotoday⁩ ⁦@OncoAlert⁩

#ASCO25 | Dr. Ong on PSA kinetics in mHSPC (IRONMAN registry): 🧬 Real-world ADT+ARPI-treated pts (n≈4,586) 📊 PSA at 6–12 mo is prognostic  • PSA ≥0.2 = poor OS/PFS  • PSA <0.1 = best outcomes 📉 PSA level stratified survival regardless of doublet vs triplet tx 📌 Supports

Congrats #MichaelOng @Soum_Roy_RadOnc for oral Ab#5002 @ASCO #ASCO25👉 https://t.co/GfN567lIqZ👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇@Daniel_J_George @OncoAlert @urotoday @PCF_Science

Ab#4505 @ASCO #ASCO25 by @DrChoueiri👉 https://t.co/mO13Ibs7Cd👉9-year follow up of Checkmate 214 #kidneycancer👉Remarkable improvement in PFS & OS w/ IPI+NIVO in pts w/ RCC, no new safety signals👇#NizarTannir @OncoAlert @urotoday @KidneyCAN @KidneyCancer

GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC

Deferred nephrectomy after ICI in mRCC—fresh data! 🔘Pathology showed 96% of specimens with necrosis, 21% of specimens showing no residual disease (pT0), and 21% exhibiting ≥95% necrosis. 🔘54% off systemic tx post-op 🔘Safe in selected patients ⚠️ Limitations: small cohort,

We are excited to host @_MiguelHernan in Houston @MDAndersonNews next week to give this year’s Melvin L. Samuels lecture (hybrid; zoom info in photo). Looking forward to the synergies that will emerge from his visit to advance rigorous causal inference methods across oncology.